Edition:
United States

TBG Diagnostics Ltd (PGLA.PK)

PGLA.PK on OTC Markets Group

--USD
--
Change (% chg)

-- (--)
Prev Close
--
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,609
52-wk High
$0.23
52-wk Low
$0.14

Latest Key Developments (Source: Significant Developments)

TBG Diagnostics enters into licensing agreement with National Taiwan University Hospital
Sunday, 12 Mar 2017 07:29pm EDT 

Tbg Diagnostics Ltd : Entered into exclusive licensing agreement with National Taiwan University Hospital for development & distribution of patented product . TBG Medigen partnership will obtain worldwide exclusive right to develop and distribute an invitro diagnostic (IVD) product .Agreement in association with Taiwan based biopharmaceutical company Medigen Corp.  Full Article

TBG Diagnostics to acquire controlling equity stake in RBC Biosciences
Tuesday, 28 Jun 2016 08:12pm EDT 

TBG Diagnostics Ltd : TBG to acquire controlling equity stake in RBC Biosciences . TBG to acquire 51% of RBC Biosciences for NT$127 million . Addition of RBC is expected to double TBG's annual sales revenues to $A8.1 million .  Full Article

TBG Diagnostics (Previously Progen Pharmaceuticals) announces sale of Pharmasynth Pty Ltd
Thursday, 3 Mar 2016 05:15pm EST 

TBG Diagnostics Ltd (previously Progen Pharmaceuticals):Sale of Pharmasynth Pty Ltd.Deal for total consideration of A$2.2 million.Entered into a binding share sale agreement (ssa) to sell Pharmasynth Pty Ltd to Luina Biotechnology Pty Ltd.  Full Article

Progen Pharmaceuticals raises $12.72 mln under offer
Friday, 11 Dec 2015 05:06am EST 

Progen Pharmaceuticals Ltd:Says Progen successfully raises $12.72 million under offer.Capital raised under the offer exceeds minimum raise target of $10 million.  Full Article

Progen Pharmaceuticals Ltd announces proposed acquisition of TBG Inc
Thursday, 30 Apr 2015 07:34pm EDT 

Progen Pharmaceuticals Ltd:Signed binding term sheet to acquire company TBG Inc.TBG is positioned as holding company focusing on global molecular diagnostics business and is dedicated to development, manufacture and marketing of nucleic acid testing kits and services.Pursuant to binding term sheet, Progen has agreed to acquire 100 pct. of TBG in return for issuing 101,722,974 new ordinary shares in Progen (being 64.8 pct. of total expanded capital base).  Full Article

More From Around the Web

BRIEF-TBG Diagnostics enters into licensing agreement with National Taiwan University Hospital

* Entered into exclusive licensing agreement with National Taiwan University Hospital for development & distribution of patented product

No consensus analysis data available.